Dermabond

Quick links to important sections

Dermabond

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dermabond

Quick Facts

Property Description
Active ingredient Ocrilate (Octyl Cyanoacrylate)
Form Liquid Monomer (transitions to Polymer Film)
Pharmacological class Tissue Adhesive / Surgical Glue
General purpose Non-invasive wound closure / Skin approximation
Origin Synthetic

What is Dermabond? Definition and Pharmacological Class

Dermabond is a sterile, single-substance product classified as a topical skin adhesive or surgical glue. It belongs to the high-level pharmacological class of tissue adhesives, functioning as a bonding entity for securing the edges of superficial wounds. This specific preparation provides a reliable, non-invasive alternative to traditional mechanical closure methods such as sutures or staples, a utility that is clinically recognized for its role in minor surgical and trauma settings. The product is administered via the topical route of administration and is designed to streamline the wound closure process by eliminating the need for needles.

Composition and Form: Ocrilate (Octyl Cyanoacrylate)

The active ingredient in this formulation is Ocrilate, which is the official adopted name for Octyl Cyanoacrylate. This active component is a synthetic chemical entity derived from the specialized chemistry of cyanoacrylates. A key feature of this product is its use of the longer-chain Octyl Cyanoacrylate, which is recognized for producing a more flexible polymer film compared to shorter-chain versions, making it suitable for areas of high skin tension. Dermabond is supplied in its dosage form as a liquid monomer within an applicator, requiring no mixing or preparation before use. Octyl Cyanoacrylate acts as the primary bonding agent for wound closure.

What is the General Purpose of This Tissue Adhesive?

The general purpose of this topical adhesive is to achieve immediate, stable tissue approximation for simple skin closure, such as closing minor lacerations that are clean and easily approximated. Upon contact with the skin's moisture, the liquid Ocrilate undergoes a process called polymerization, rapidly transforming into a flexible, protective solid polymer film. This strong film effectively holds the wound edges together, creating a durable and water-resistant barrier that supports the natural healing process.

Regulatory References

  1. clinically recognized for its role in minor surgical and trauma settings

What side effects are possible with Dermabond?

Possible Side Effects and Safety Information

The safety profile of Dermabond (Octyl Cyanoacrylate) is established through official regulatory documentation, detailing the range of officially reported adverse reactions and safety constraints. The majority of documented effects are local reactions occurring at the application site.

Documented Adverse Reactions and Frequencies

Adverse reactions reported in clinical studies primarily involve local tissue response and are classified by frequency based on incidence rates:

Classification Examples of Documented Reactions
Most Frequent Erythema (Redness)
Common Edema (Swelling), Pain, Suspected Infection, Warmth, Wound Dehiscence

These effects are generally categorized within Skin and Subcutaneous Tissue Disorders and General Disorders and Administration Site Conditions in regulatory reports.

Clinically Significant and Population Safety Notes

The regulatory safety record includes the documentation of serious adverse reactions, specifically rare instances of severe localized infection, such as cellulitis progressing to an abscess requiring surgical intervention, associated with suspected infection.

Specific observations have been made regarding certain patient groups. An increased rate of suspected infection was reported in the pediatric population (patients under 12 years old) in the clinical trial data. Furthermore, the safety and effectiveness of the product have not been studied in patients with conditions such as peripheral vascular disease or a history of keloid formation.

Safety Constraints

The use of the tissue adhesive is formally contraindicated in individuals with a known hypersensitivity to cyanoacrylate or formaldehyde (a breakdown product). Due to the exothermic nature of the process, a sensation of heat or discomfort occurs immediately upon application. The label also notes that the non-absorbable polymer should not be used below the skin surface due to the potential for a foreign body reaction.

Overdose and Emergency Response

When to Seek Urgent Medical Help

As a topical skin adhesive medical device, Dermabond does not have a conventional pharmacological overdose profile involving dose-related symptom clusters.

Urgent medical attention is instead required for serious adverse events or complications that arise from contraindications or misuse. Patients should seek immediate care if any signs of a severe allergic reaction occur, particularly in individuals with a known hypersensitivity to the adhesive's components, which include cyanoacrylate or formaldehyde.

Specific instances that necessitate urgent medical evaluation include:

  • Severe Allergic or Hypersensitivity Reaction: Signs of a severe or widespread skin reaction, such as a contact dermatitis, rash, or significant swelling near the application site, especially if accompanied by systemic symptoms.
  • Inadvertent Eye Contact: If the liquid adhesive comes into contact with the eye, immediate and copius flushing with water or saline is required, followed by ophthalmological consultation if the adhesive remains or if adverse symptoms develop.
  • Wound Complications: Any evidence of wound infection, such as fever, purulent drainage, increasing redness spreading beyond the wound edges, or significant pain and warmth.

Using this product on wounds with an existing active infection, gangrene, or decubitus etiology is strictly contraindicated and can lead to severe complications that require professional intervention.

Therapeutic Uses of Dermabond

What Dermabond Treats: Main Uses and Benefits

Dermabond is a topical skin adhesive used to achieve secure, non-invasive closure in specific clinical situations. Its utility plays a role in managing superficial tissue breaks, infection risks, and the burdens associated with traditional closure methods. The adhesive is intended for topical application to hold closed the easily approximated skin edges of wounds.

Therapeutic Scope and Patient Benefits

This adhesive is indicated for the effective tissue approximation of clean, easily approximated minor lacerations resulting from trauma and for closing superficial surgical incisions. This commonly includes closure after procedures such as minimally invasive, gynecologic, or orthopaedic surgery. Its application supports the management of compromised dermal integrity by providing a continuous surface seal, which generally supports the healing process.

A key therapeutic benefit is the provision of a supportive, water-resistant barrier that helps close the wound from the external environment. This protective layer helps block the entry of contaminants and is relevant in contexts involving supportive management of infection risk. Thereby, it assists in managing the overall risk of wound infection during the initial recovery period.

Practical Comfort and Enhanced Cosmetic Outcome

“The closure technique is commonly associated with an improved cosmetic appearance of the healed wound, offering symptomatic relief that helps patients cope more steadily with difficult episodes.”

The use of this adhesive provides helpful practical benefits to the patient, directly addressing the inconvenience of mechanical closures.


Quick Facts: Relief for Inconvenience

Domain Description
Symptom Cluster Managed Inconvenience of mechanical closures (suture/staple removal).
Conditions Managed Minor lacerations and superficial surgical incisions.
Key Patient Benefit Supports easing the overall symptom load by eliminating need for removal procedure, relevant for pediatric patients.

Eligibility and Restrictions for Use

Who can and cannot use Dermabond?

Dermabond eligibility is strictly defined by regulatory labeling, prioritizing the wound's condition and location over systemic patient factors.

Eligible Populations: The adhesive is indicated for the topical closure of clean, easily approximated skin edges of minor lacerations and superficial surgical incisions. It is generally suitable for use in both pediatric and older adult patients when the specific wound criteria are met.

Absolute Contraindications (Who Must Not Use): Use is contraindicated in patients with a known hypersensitivity to cyanoacrylate or its components. It must not be applied to wounds that are actively infected, complex wounds (like puncture wounds or bites), or deep wounds involving fascia or muscle. Application is also prohibited on mucosal surfaces and near the eye.

Use Not Established / Restrictions: Safety and effectiveness have not been established in pregnant or breastfeeding women. Use is restricted on wounds under strong tension or those subject to constant friction. Safety has also not been studied in patients with certain comorbidities, including peripheral vascular disease or blood clotting disorders.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for this topical tissue adhesive focuses on functional and physical interactions that compromise the integrity of the polymer film, rather than systemic drug-drug interactions. The documentation indicates no documented systemic pharmacokinetic or pharmacodynamic interactions with other medicinal products. The profile also lists no specific systemic drug combination as formally contraindicated.

Interaction-Related Restrictions and Timing Rules

The most significant constraints involve co-administration timing and topical product use:

  • Topical Chemical Interference: Co-administration with certain substances is restricted. Liquid medications, ointment medications, and topical antibiotics must not be applied to the wound after closure with the adhesive. This mandatory restriction is necessary because these substances are documented to weaken the polymerized film, leading to a potential loss of wound approximation.
  • Polymerization Function Interference: A timing rule applies during application. The adhesive must not be applied to wet wounds or to areas containing fluids with alcohol. These substances are officially documented to accelerate the polymerization process, which interferes with the formation of a proper, durable bond.
  • Chemical Degrading Agents: Substances such as petroleum jelly and acetone are documented to interact chemically with the product, specifically acting as agents that can be used to loosen the adhesive bond.

The official interaction structure is thus defined solely by these physical constraints at the application site.

Mechanism of Action

How Dermabond Works

The mechanism of Dermabond (Octyl Cyanoacrylate) is purely physicochemical, relying on a rapid, targeted chemical process rather than acting on biological receptors or enzymes. Its function is to create a dynamic, physical bond that maintains the integrity of the skin layer.


️ Rapid Polymerization and Chemical Initiation

This process is initiated when the liquid monomer contacts tissue surface moisture (water) and nucleophilic groups on the skin proteins. This exposure triggers an anionic polymerization —a fast, exothermic reaction that converts the small liquid molecules into a long-chain, solid polymer structure within seconds, thus providing a rapid onset of its physical effect.


Tissue Adhesion and Mechanical Stabilization

The solid polymer forms strong covalent anchors with the amine and thiol groups found in the superficial keratin and other skin proteins. This chemical adhesion produces a flexible, tenacious film that physically bridges the wound edges, imparting tensile strength and creating immediate mechanical reinforcement of the approximated tissue.


️ Barrier Function and Hydrolytic Degradation

The resulting film acts as a seamless, water-resistant occlusive barrier that separates the underlying tissue from the external environment, acting as a physical shield. Furthermore, the polymer is designed for gradual breakdown via hydrolysis from contact with tissue fluids, ensuring the mechanical support naturally dissipates over 5 to 10 days as the epidermal layer renews.

Dosage and Administration Information

Instruction Map: How to use Dermabond — Official Administration Guidelines

This map describes the administration of Dermabond (2-octyl cyanoacrylate) based on the explicit instructions and principles documented for this product and its associated prescribing information.


Administration Scope

Feature Description
Route of administration Topical Application to the surface of the skin.
Dosing schedule Application regimen depends on the product version: standard formulations require multiple thin layers (often three or more), while high-viscosity products are applied in a single continuous layer.
Preparation requirements (if applicable) The wound site must be thoroughly cleansed, and complete hemostasis (stoppage of bleeding) must be established. The area must be patted dry to allow proper bonding.
Age-group administration rules No specific dose adjustments are detailed for age groups, as the device is not systemically absorbed. Procedural caution is noted for application near the eyes, ears, or nose.
Special procedural conditions The adhesive is intended to be used in conjunction with, but not as a replacement for, deep dermal (subcuticular) sutures. Do not apply liquid or ointment medications to the polymerized film.

Instruction Classifications (High-Level)

Feature Description
Administration method type Topical (Liquid monomer applied to skin surface).
Frequency pattern Single application per wound closure procedure.
Regulatory basis Standard manufacturer guidelines and associated instructions.
Use-context constraints The adhesive bond typically remains in place for 5 to 10 days, sloughing off naturally as the skin heals beneath it.

Resulting Procedural Structure

Official step sequence:

  • The applicator is prepared and the liquid adhesive must be used immediately after crushing the inner ampule.
  • The skin edges are approximated and held together.
  • The adhesive is applied in the required layer pattern over the approximated edges.
  • Manual approximation is maintained for approximately 60 seconds after the final application to ensure initial setting.

Connection to the overall use protocol: The official instructions establish a standardized, procedural approach beginning with the critical step of ensuring the application site is dry and non-bleeding, a prerequisite for successful polymerization. This is followed by a regimen that specifies either multiple thin layers or a single continuous layer depending on the specific formulation. Adherence to the 60-second approximation time and the avoidance of topical ointments post-application are essential for maintaining the integrity and intended duration of the seal.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dermabond

Evidence for Use in Simple Trauma-Induced Lacerations

The research for this type of tissue adhesive, specifically Octyl Cyanoacrylate, was evaluated in major Randomized Controlled Trials (RCTs), which research examined closure patterns compared to traditional methods like sutures. Studies monitored several outcomes related to physical discomfort, including wound dehiscence (wound separation), outcomes linked to inflammatory or irritative states such as wound infection rates, and the total procedure time. Research also focused on the final assessment of cosmetic outcome (scar appearance).

Findings describe patterns observed in the studies. For short-term outcomes such as wound dehiscence and infection incidence, the adhesive was studied in trials that reported measurements similar to those for sutures in the populations studied. Research describes that the time needed for the closure procedure was often reported in specific intervals relative to comparator methods.

Evidence for Use in Superficial Surgical Incisions

Research exploring the use of the adhesive to close the outer layer of skin after surgery also includes numerous RCTs and controlled clinical studies. These studies monitored outcomes across various surgical specialties, including gynecologic, general, and orthopaedic procedures. The main outcomes monitored included the occurrence of wound dehiscence, incidence of Surgical Site Infection (SSI), evaluation of cosmetic outcome, and the time taken for the closure procedure.

Studies monitored patterns related to wound healing complications. Trials reported the rates of SSI and dehiscence observed in the study groups. Research describes that the time required to complete the closure procedure was often reported in specific intervals relative to comparator methods. Patient-reported outcomes describing perceived discomfort was studied for during the healing process.

What is Still Uncertain About Dermabond Evidence

Long-term effects are not fully established concerning the consistency of results for cosmetic outcomes, with findings varying across different studies. The available follow-up durations were limited in many key trials, meaning effects are not fully characterized across the broader population of patients who receive the product. Comparative evidence is lacking for the use of the adhesive alone for incisions located in areas of high mechanical tension. For other groups, such as older adults or those with significant conditions involving periods of heightened symptoms, data for certain groups remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Dermabond (FAQ)

Q: Is Dermabond the same as the common household product known as 'super glue'?

A: According to official information, Dermabond uses octyl cyanoacrylate, which is a specific, longer-chain chemical, while common household super glues often contain the shorter-chain ethyl cyanoacrylate. This longer-chain structure is generally recognized for its reduced tendency to cause local inflammatory reactions and for providing a flexible polymer bond.


Q: What should be done if the adhesive film starts lifting at the edges?

A: Official patient instructions advise against actions like scratching, rubbing, or picking at the adhesive film, as this may cause it to loosen before the skin has fully healed underneath. If the wound edges appear to be separating or pulling apart, official documentation advises seeking guidance from a healthcare provider.


Q: Can the wound be washed or allowed to get wet while Dermabond is in place?

A: Official instructions state that the wound should be kept dry for the initial 24 to 48 hours after application. After this initial period, brief wetting, such as showering, may be permitted. However, official instructions note that the wound should not be soaked, submerged (e.g., swimming), or scrubbed while the adhesive is in place.


Q: Is it necessary to completely keep the area dry for a specific period after application?

A: Yes, the product instructions specify that the wound area should be kept completely dry for the first 24 to 48 hours following the adhesive application. Following this brief period, care instructions indicate that gentle, brief wetting, followed by immediate drying, is generally permissible.


Q: Are there known concerns or research on using Dermabond on areas with dense hair?

A: The product's contraindications note that the adhesive should not be applied to skin that has dense natural hair (such as the scalp). The product's contraindications also include skin that may be regularly exposed to body fluids.


Q: Can sun exposure or tanning affect how long the Dermabond closure lasts?

A: The official product information advises patients to protect the wound area from prolonged sun exposure or tanning lamps while the adhesive film remains in place. This instruction is provided to help maintain the intended integrity and duration of the adhesive closure.


Q: What are the key instructions for keeping the Dermabond closure clean?

A: Official instructions advise that the closure should not be scrubbed or cleaned vigorously. If the area gets wet after the initial drying period, it should be dried immediately by gently blotting it with a soft towel or cloth.


Q: How soon after application can most people return to their usual exercise routine?

A: Official instructions state that this restriction is in effect until the adhesive has naturally sloughed off, which typically occurs within 5 to 10 days. Patients should avoid strenuous physical activity that could cause tension on the wound or lead to heavy perspiration.


Q: Are there official recommendations regarding when to seek follow-up care for a Dermabond-closed wound?

A: Official instructions state that a healthcare provider should be contacted if the wound opens up or if signs of potential infection are observed. These signs can include increasing redness, swelling, warmth, pain, or fever.


Q: What is the typical timeframe for a wound closed with Dermabond to be considered healed?

A: The adhesive film is designed to remain in place until the wound or incision has properly healed, which official product information generally states takes between 5 to 10 days. The film will slough off naturally as the skin heals beneath it.


Q: What are the official differences between using Dermabond and using traditional medical stitches?

A: Studies comparing the adhesive to sutures note that the adhesive is associated with a shorter procedure time and less patient pain for managing simple lacerations. Furthermore, because the adhesive sloughs off naturally, there is no need for a follow-up visit for removal, unlike with traditional stitches.


Q: What are the official care instructions for a wound that has been closed with Dermabond?

A: Official patient care instructions advise against applying topical liquid medications, ointment medications, or petroleum jelly to the closure. It also states that the wound should not be scrubbed or soaked and should be protected from direct injury to ensure the adhesive bond remains intact.


Q: If redness appears around the edges of the wound, what might the official labeling suggest that indicates?

A: Redness (erythema) is a commonly reported adverse reaction. However, increasing redness, especially when paired with symptoms like pain, swelling, warmth, or fever, is listed in patient instructions as a potential sign of infection that may require consultation with a healthcare professional.


Q: Are there specific depth or length limitations for wounds where Dermabond can be used?

A: The product is officially indicated for closing clean, easily approximated skin edges of wounds and superficial surgical incisions. Official documentation notes that it should not be used on deep wounds that involve muscle or fascia.


Q: Where can I find the official prescribing information or package insert for Dermabond?

A: The complete regulatory details, including the Indications for Use, Warnings, and Precautions, are contained within the official Instructions for Use (IFU) or Package Insert. This documentation is provided with the device and is also publicly available through regulatory websites like the FDA's database.


Q: How does the chemical composition of Dermabond differ from other common medical glues?

A: Dermabond utilizes the longer-chain chemical octyl cyanoacrylate. Official reports note that this structure is designed to lead to a slower breakdown process on the skin, which helps reduce the release of degradation products when compared to some older or shorter-chain medical glues.


Q: Does the location of the wound (e.g., a joint) affect the durability of the adhesive closure?

A: Yes, the official contraindications specify that the product should not be used in high skin tension areas or across areas of increased tension, such as joints like the knuckles or knees. Official documentation indicates this restriction applies unless the area is fully immobilized during the healing period.


Q: Does the application of Dermabond affect the long-term appearance of the healed wound?

A: Studies have associated the use of the adhesive with excellent cosmetic appearance and equivalent outcomes compared to sutures in various trials. Official patient care instructions mention sun protection for up to two years as the final scar appearance matures.


Q: Are there specific side effects or adverse events listed in the official documentation as being rare?

A: While most documented effects are local and common, the official safety record includes reporting of serious adverse reactions. These have included rare instances of severe localized infection, such as cellulitis progressing to an abscess requiring surgical intervention.


Q: Does Dermabond provide a complete barrier against bacteria entering the wound?

A: Studies and official information indicate that the adhesive forms a microbial barrier that provides significant protection (99% in vitro for 72 hours) against a list of organisms commonly responsible for Surgical Site Infections (SSIs).


Q: Why is Dermabond described as a skin adhesive and not a tissue adhesive?

A: The product is officially described as a topical skin adhesive because its FDA-approved use is strictly for application to the surface of the skin. Official documentation specifies that it should not be used below the skin surface because the material is non-absorbable and could cause a foreign body reaction.

How should Dermabond be stored and disposed of?

How to Store and Dispose of Dermabond

Dermabond Topical Skin Adhesive must be stored under specific environmental conditions to maintain its chemical stability, as required by regulatory labeling.

Storage Requirements

Condition Requirement
Temperature Store below 30 C (86 F) and keep away from direct heat.
Protection Store in its original, tightly closed container, protected from direct sunlight and moisture.
Safety Must be kept out of the reach of children.

Disposal and Handling

The adhesive is supplied as a sterile, single-use applicator and must not be resterilized. The product should not be used past its expiry date. Any remaining opened material must be discarded immediately after the single procedure. Disposal of the used or unused product must be done in accordance with local, state, and federal regulations; it is prohibited to release the product into the environment, including flushing it into surface water or the sanitary sewer system.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Dermabond found in:

A-Z Index: